The mRNA Therapeutics market is expanding due to advancements in drug development, personalized medicine, and delivery technologies. Opportunities arise from the technology's success in vaccines and ...

Return on Equity (ROE): Arcturus Therapeutics's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -5.93%, the company showcases ...

Market to Reach $430 Million by 2032, Driven by Breakthrough Clinical Trials and Expanding Indications. The global RNA-Based Therape ...

NIH director Jay Bhattacharya has offered a new explanation for why the federal government canceled $500 million in contracts ...

The U.S. Food and Drug Administration (FDA) is unlikely to renew the authorization granted to use Pfizer (NYSE:PFE) and BioNTech’s (BNTX) COVID-19 vaccine in young children this fall, The Guardian ...

Known as promoter-proximal pausing, this interruption in the transcription activity of RNA polymerase II—the enzyme ...

NIH Director Jay Bhattacharya offered an explanation for the cancellation of mRNA vaccine contracts that didn't align with ...

After BioNTech’s acquisition of CureVac closes, BioNTech will pay GSK another $130 million and a 1% royalty on rest-of-world ...

The Department of Health and Human Services announced Thursday that it will cut nearly half a billion dollars in funding for 22 vaccine development programs, many of which ...

Trump administration has unwisely cancelled mRNA vaccine research while doing little about Americans’ unhealthy diet.

This week, President Donald Trump called Operation Warp Speed, a public-private federal program that helped speed up the ...

The future of mRNA cancer immunotherapies is uncertain after Health and Human Services Secretary Robert F. Kennedy Jr. defunded 22 mRNA vaccine projects for flu and COVID-19.